Scientific Industries Reports Financial Results for Second Quarter 2023
Benchtop Lab Equipment Revenue Up Led by Torbal Division's 48% Increase - Bioprocessing Revenue Up 41%BOHEMIA, NY / ACCESSWIRE /...
Pharmaceutical
GE HealthCare Receives FDA Clearance for Portrait Mobile, A First-Of-Its-Kind, Wireless Monitoring Solution Aiding Early Detection of Patient Deterioration
GE HealthCare’s smart phone-sized Portrait Mobile frees the patient from the hospital bed while providing continuous monitoring of vital signs,...
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Data presented at the 2023 SNO/ASCO CNS Cancer ConferenceBerubicin currently being evaluated in an ongoing potentially pivotal study for the...
Jaguar Health Reports Second Quarter 2023 Financial Results
Net revenue increased 36% in Q2 2023 versus Q1 2023Top line results expected late October 2023 for company's phase 3...
Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update
Combination study of SON-1010 with Roche's atezolizumab (Tecentriq®) has been initiated in AustraliaFirst SON-1010 Phase 1 study has been completed...
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
Continued rapid pace of enrollment with ~75% of expected patients now enrolled in ongoing potentially pivotal study evaluating Berubicin for...
Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression
Lead Asset KET01, an Oral Prolonged-Release Ketamine Formulation, Demonstrated Early Improvements in Depressive Severity Key Findings Included Minimal Incidences of...
Allogene Therapeutics Appoints Earl Douglas as General Counsel
Earl Douglas General Counsel, Allogene TherapeuticsSOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO),...
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment...
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
Tel Aviv, Israel / Vancouver, Canada, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)...
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd.MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a...
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024...
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company...
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to launch a Phase 2a biomarker...
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab...
InnovAge Strengthens Board with Appointment of New Independent Director
InnovAge Strengthens Board with Appointment of New Independent Director InnovAge Appoints Teresa Sparks to its Board of DirectorsDENVER, Aug. 14,...
Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) in patients...
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective...
Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
San Diego, California--(Newsfile Corp. - August 14, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing a...
Scientific Industries to Report Second Quarter 2023 Financial Results on August 14, 2023
Investor Call to be held Tuesday, August 15th at 11:00 AM Eastern TimeBOHEMIA, NY / ACCESSWIRE / August 11, 2023...